Company profile
NXI Therapeutics AG
NXI Therapeutics intends to commence operations with screening and preclinical development of compounds that interfere with coronin 1-dependent T cell activation in autoimmune diseases and organ transplantation. A biomarker and a diagnostic program targeted towards the development of assay systems to analyse the effectiveness of the therapy and naïve T cell populations for use in patients undergoing immunosuppression is optional.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
